The effect of venous thrombolysis treatment of acute ischemic stroke with Ginkgo Injection combined with Alteplase
YU Libo1 WANG Shuai1 JIANG Ying2 GU Jiumei2
1.The Imaging Center, Chinese People′s Liberation Army 211 Hospital, Heilongjiang Province, Harbin 150000, China;
2.The Second Division of Neurology Department, Chinese People′s Liberation Army 211 Hospital, Heilongjiang Province, Harbin 150000, China
Abstract：Objective To explore effect of venous thrombolysis treatment of acute ischemic stroke with Ginkgo Injection combined with Alteplase. Methods A total of 106 cases′ clinical data of acute ischemic stroke in the Second Division of Neurology Department, Chinese People′s Liberation Army 211 Hospital from May 2015 to July 2017 were selected and analyzed. All the cases were divided by different treatment method, with 53 cases in the control group (Alteplase therapy) and 53 cases in the observation group (Ginkgo Injection combined with Alteplase therapy). The two groups were treated for 14 days. The National Institute of Health Stroke Scale (NIHSS) scores, improve mRS score, fibrinogen (FIB), prothrombin time (PT), thrombin time (TT), life quality scores, activity of daily living Barthel index of the two groups were observed and the clinical efficacy, complications of the two groups were observed. Results Before treatment, the NIHSS scores, improve mRS scores, FIB, PT, TT, life quality scores and Barthel index of two groups were compared and there was no statistically significant differences (P ＞ 0.05). After treatment, the NIHSS scores, improve mRS scores in the two groups were lower than those in the two groups, life quality scores and Barthel index in the two groups were higher than those before treatment, the differences were significant (P ＜ 0.05). After treatment, the NIHSS scores, improve mRS scores in the observation group were lower than those in the control group while the life quality scores and Barthel index were higher than those in the control group, the differences were significant (P ＜ 0.05). After treatment, FIB was lower than that before treatment and PT, TT were higher than those before treatment in the control group (P ＜ 0.05). But there was no significant difference between FIB, PT, TT before and after treatment in the treatment group (P ＞ 0.05). After treatment, FIB in the observation group was higher than that in the control group and PT, TT were lower than those in the control group, all the differences were statistically significant (P ＜ 0.05). The total clinical treatment efficiency of the observation group was higher than that in the control group, and total complications rate were lower than the control group, the differences were statistically significant (P ＜ 0.05). Conclusion The venous thrombolysis treatment of acute ischemic stroke with Ginkgo Injection combined with Alteplase could improve nerve function and life quality, by which the influence of blood coagulation dysfunction is little, the effect is remarkble, complications is few, and it is worth of promotion.
[1] Tsivgoulis G，Zand R，Katsanos AH，et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden：a meta-analysis [J]. JAMA Neurol，2016，73（6）：675-683.
[2] 石宝洋，靳航，杨弋.急性缺血性脑卒中阿替普酶静脉溶栓相关并发症的临床研究进展[J].中风与神经疾病杂志，2018，35（3）：275-278.
[3] 孙永兴，刘玉祥，张凝远.急性缺血性脑卒中阿替普酶静脉溶栓治疗28例临床分析[J].重庆医学，2015，44（15）：2120-2121.
[4] Karlinski M，Kobayashi A，Czlonkowska A，et al. Intravenous thrombolysis for stroke recurring within 3 months from the previous event [J]. Stroke，2015，46（11）：3184-3189.
[5] 王蕾，姜帅，何柳，等.急性缺血性脑卒中超早期阿替普酶静脉溶栓155例临床研究[J].中国药业，2017，26（21）：35-38.
[6] Romano JG，Smith EE，Liang L，et al. Outcomes in mild acute is chemic stroke treated with intravenous thrombolysis [J]. JAMA Neurol，2015，72（4）：423-431.
[7] 焦荣红，牛慧敏，靳伟.醒脑静注射液联合阿替普酶对急性缺血性脑卒中患者炎性因子和颅内血流速度的影响[J].河北医药，2015，27（24）：3719-3722.
[8] Padjen V，Bodenant M，Jovanovic DR，et al. Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia [J]. J Neurol，2013，260（12）：3049-3054.
[9] 沈李，楼秋丽，马韩飞.醒脑静注射液联合阿替普酶治疗急性缺血性脑卒中疗效观察及对患者认知功能的影响[J].新中医，2017，49（4）：14-16.
[10] Eriksson M，Norrving B，Terént A，et al. Functional outcome 3months after stroke predicts long-term survival [J]. Cerebrovasc Dis，2008，25（5）：423-429.
[11] Husted JA，Cladman DD，Farewell VT，et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis [J]. J Rheumatol，1997，24（3）：511-517.
[12] 王新德.实用临床神经病学[M].北京：科学技术文献出版社，2007：619-620，630.
[13] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[14] 王炎强，孙绍洋，张炳俊，等.大动脉粥样硬化性首发急性缺血性卒中的危险因素与分布特点[J].中国神经精神疾病杂志，2016，42（4）：222-227.
[15] Yang G，Wang Y，Zeng Y，et al. Rapid health transition in China 1990-2010：findings from the Global Burden of Disease Study 2010 [J]. Lancet，2013，381（9882）：1987-2015.
[16] 李聪，代英杰，郭东，等.银杏内酯注射液联合阿替普酶治疗大动脉粥样硬化性缺血性脑卒中的临床观察研究[J].中风与神经疾病杂志，2017，34（8）：729-731.
[17] Jauch EC，Saver JL，Adams HP，et al. Guidelines for the early management of patients with acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. Stroke，2013，44（3）：870-947.
[18] 张辉，秦旋，赵德福，等.银杏内酯注射液治疗脑卒中基底动脉闭塞后再通1例[J].中国实用神经疾病杂志，2016， 19（23）：128，142.
[19] 曹磊，兰新新，王林晓，等.银杏内酯注射液对大鼠急性期脑缺血再灌注损伤的保护作用[J].中国临床药理学与治疗学，2015，20（7）：721-726.
[20] 雷建明，钟雪华，华国操，等.银杏内酯注射液联合阿司匹林治疗缺血性脑卒中的临床观察[J].广东医科大学学报，2017，35（3）：234-236.
2019, Vol. 16 
京公网安备 11010502046598号